Affimers: a novel biotherapeutic platform for the treatment of cancer

Promexus是一家新的生物技术公司，该公司将开发一种新的人类治疗性蛋白质(仿射)，该蛋白质将解决目前基于抗体的药物的一些缺点。抗体在治疗多种人类疾病方面非常成功，如哮喘、关节炎和癌症，但它们的生产成本很高，而且由于它们的体积很大，只能通过注射给药。仿真剂的制造成本应该更低，因为它们更小、更稳定，可以局部使用(例如，作为乳膏涂在皮肤上或使用吸入器喷到肺部)。我们的第一种药物将用于治疗癌症，因为癌症需要更便宜、更有效的药物。仿生剂具有的所有性质都将使下一代治疗药物满足新药的需求

Promexus is a new biotechnology company which will be developing a novel humantherapeutic protein (the Affimer) that will address some of the shortcomings of the currentantibody based drugs. Antibodies have been very successful at treating a wide range of humandisease such as asthma, arthritis and cancer, but they are expensive to produce and because oftheir large size can only be given via an injection. Affimers should be cheaper to make andbecause they are smaller and stable, can be administered topically (for example to the skin asa cream or to the lungs using an inhaler). Our first drug will be for the treatment of cancerwhere there is a need for cheaper more effective drugs. Affimers have all the properties topotentially make the next generation of therapeutics to meet the demand of new medicines